TNF and cancer: Immunotherapeutic modalities—including checkpoint inhibitors (PD-1/PD-L1, CTLA-4), CAR-T and CAR-NK cell therapies, cytokine-based treatments (e.g., IL-2, TNF-α), cancer vaccines, and oncolytic viruses—are all susceptible to immune remodeling induced by μg.